OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
6931$43.6057

Qing Song Health Co Ltd

Healthcare Facilities & ServicesVerified

Qing Song Health maintains a debt-to-equity ratio of 1.05 and a current ratio of 3.93, indicating moderate leverage and strong short-term liquidity. The company's liquidity position is further supported by a price-to-book ratio of 2.52 and a tangible book ratio of 2.52, suggesting that the market values the company's equity at a premium to its book value. However, the company reported negative operating cash flow of -71.63 million TWD, which may signal near-term liquidity challenges if not offset by free cash flow generation. Profitability metrics show a return on equity (ROE) of 8.02% and a return on assets (ROA) of 3.55%, both below the industry median for Healthcare Facilities & Services. The company's operating margin is 5.08% (calculated as operating income of 57.03 million TWD divided by revenue of 1.12 billion TWD), which is also below the industry average for margin-driven healthcare services. Gross margin stands at 13.16% (147.62 million TWD gross profit on 1.12 billion TWD revenue), indicating moderate cost control in service delivery. The company's revenue is concentrated in long-term residential care services, with disclosed segments including institutional care, day care centers, and home-based services. No geographic diversification is reported, and the company operates primarily in Taiwan. This concentration may expose the company to local regulatory and demographic risks, particularly in an aging population context. Growth trajectory is constrained by a negative operating cash flow and a free cash flow of 103.22 million TWD, which is insufficient to cover capital expenditures of -80.49 million TWD. The company's revenue history shows a stable but modest growth rate, with no significant acceleration in the current fiscal year. The outlook for the next fiscal year remains neutral, with no material revenue growth expected. Risk factors include a medium liquidity risk due to negative net cash and a debt load of 1.2 billion TWD. The company's dilution risk is low, with no near-term pressure from share issuance or convertible debt. However, the company's reliance on long-term debt and the absence of a cash buffer may increase financial risk in a rising interest rate environment. Recent filings and transcripts indicate no material changes in business strategy or regulatory exposure. The company continues to focus on expanding its residential care capacity and improving service efficiency.

30-day price · 6931-10.40 (-20.4%)
Low$40.60High$51.80Close$40.60As of15 May, 00:00 UTC
Profile
CompanyQing Song Health Co Ltd
Ticker6931.TW
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Qing Song Health Co Ltd provides residential long-term care services for the elderly, including 24-hour institutional care, day care centers, and home-based services, as well as facility management consulting and care consumables sales.

Classification. Qing Song Health is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Qing Song Health maintains a debt-to-equity ratio of 1.05 and a current ratio of 3.93, indicating moderate leverage and strong short-term liquidity. The company's liquidity position is further supported by a price-to-book ratio of 2.52 and a tangible book ratio of 2.52, suggesting that the market values the company's equity at a premium to its book value. However, the company reported negative operating cash flow of -71.63 million TWD, which may signal near-term liquidity challenges if not offset by free cash flow generation. Profitability metrics show a return on equity (ROE) of 8.02% and a return on assets (ROA) of 3.55%, both below the industry median for Healthcare Facilities & Services. The company's operating margin is 5.08% (calculated as operating income of 57.03 million TWD divided by revenue of 1.12 billion TWD), which is also below the industry average for margin-driven healthcare services. Gross margin stands at 13.16% (147.62 million TWD gross profit on 1.12 billion TWD revenue), indicating moderate cost control in service delivery. The company's revenue is concentrated in long-term residential care services, with disclosed segments including institutional care, day care centers, and home-based services. No geographic diversification is reported, and the company operates primarily in Taiwan. This concentration may expose the company to local regulatory and demographic risks, particularly in an aging population context. Growth trajectory is constrained by a negative operating cash flow and a free cash flow of 103.22 million TWD, which is insufficient to cover capital expenditures of -80.49 million TWD. The company's revenue history shows a stable but modest growth rate, with no significant acceleration in the current fiscal year. The outlook for the next fiscal year remains neutral, with no material revenue growth expected. Risk factors include a medium liquidity risk due to negative net cash and a debt load of 1.2 billion TWD. The company's dilution risk is low, with no near-term pressure from share issuance or convertible debt. However, the company's reliance on long-term debt and the absence of a cash buffer may increase financial risk in a rising interest rate environment. Recent filings and transcripts indicate no material changes in business strategy or regulatory exposure. The company continues to focus on expanding its residential care capacity and improving service efficiency.
Key takeaways
  • Qing Song Health has a strong current ratio of 3.93 but faces liquidity challenges due to negative operating cash flow.
  • ROE of 8.02% and ROA of 3.55% are below industry medians, indicating suboptimal capital efficiency.
  • Revenue is concentrated in long-term residential care services with no geographic diversification.
  • Free cash flow of 103.22 million TWD is insufficient to cover capital expenditures, limiting growth capacity.
  • Debt load of 1.2 billion TWD and negative net cash raise concerns about financial flexibility.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$1.12B
Gross profit$147.6M
Operating income$57.0M
Net income$91.7M
R&D
SG&A
D&A
SBC
Operating cash flow-$71.6M
CapEx-$80.5M
Free cash flow$103.2M
Total assets$2.58B
Total liabilities$1.44B
Total equity$1.14B
Cash & equivalents$31.7M
Long-term debt$1.20B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$43.60
Market cap$2.88B
Enterprise value$4.06B
P/E31.4
Reported non-GAAP P/E
EV/Revenue3.6
EV/Op income71.1
EV/OCF
P/B2.5
P/Tangible book2.5
Tangible book$1.14B
Net cash-$1.17B
Current ratio3.9
Debt/Equity1.1
ROA3.5%
ROE8.0%
Cash conversion-78.0%
CapEx/Revenue-7.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
Metric6931Activity
Op margin5.1%11.5% medp25 9.9% · p75 15.0%bottom quartile
Net margin8.2%8.6% medp25 6.3% · p75 12.4%below median
Gross margin13.2%28.8% medp25 28.8% · p75 28.8%bottom quartile
CapEx / revenue-7.2%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity105.0%71.3% medp25 60.7% · p75 71.3%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 11:03 UTC#ce1a5e27
Market quoteclose TWD 43.60 · shares 0.07B diluted
no public URL
2026-05-10 11:03 UTC#3c692b0d
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 11:06 UTCJob: 954ed537